References

1. Goldsack JC, Coravos A, Bakker JP, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digit Med. 2020;3:55. doi:10.1038/s41746-020-0260-4

2. Byrom B, Watson C, Doll H, et al. Selection of and evidentiary considerations for wearable devices and their measurements for use in regulatory decision making: recommendations from the ePRO Consortium. Value Health. 2018;21:631-639.

3. Walton M, Cappelleri J, Byrom B, et al. Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials. Contemp Clin Trials. 2020;91:105962.

4. US Food and Drug Administration. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Guidance for Industry, Investigators, and Other Stakeholders. FDA; 2021.

5. Catellier DJ, Hannan PJ, Murray DM, et al. Imputation of missing data when measuring physical activity by accelerometry. Med Sci Sports Exerc. 2005;37(11 suppl):S555-S562.

6. Di J, Demanuele C, Ketterman A, et al. Considerations to address missing data when deriving clinical trial endpoints from digital health technologies. Contemp Clin Trials. 2022;111:106594.